Stockreport

OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes [Yahoo! Finance]

OS Therapies Incorporated  (OSTX) 
PDF Company to host conference call later in April 2026 to review new biomarker signature Biomarker signature meets pharmacodynamic/response criteria established by FDA's [Read more]